Treatment with Mavenclad increased quality of life after one year of treatment instead of two, and the effect was long-lasting, according to data from two phase IV studies.
Mafenclad (Cladribin), taken as tablets, attacks lymphocytes that are thought to be critical to disease progression in multiple sclerosis. This is a short treatment and then it has a long effect after the treatment itself.
At an MS conference, Ectrim recently presented Merck . data From the ongoing Phase IV study, which showed improvement in both physical and mental health in 426 patients with relapsing-remitting MS after one year of approved treatment for two years.
At the same time, data from another Phase IV study, which examines the long-term effect in 435 people with relapsing-remitting MS, are also reported. Of these, 90 percent were treated with cladribine tablets in previous double-blind, randomized, phase III studies.
The median follow-up in the study was 10.9 years and just over half (55.8 percent) of those who received cladribine tablets did not require further treatment.
– It is a huge step forward that today in additional studies we can confirm the effect of Mavenclad. The same mechanism of action spoke in favor of this finding, and now in two different studies we can show the increased quality of life and the long-term effect, he says. Anders WeslauMerck CEO, in a press release.
George Eliot is a contributor to Dealmakerz, covering news, politics, business, technology, sport, entertainment, and lifestyle. She focuses on clear, accurate reporting and useful information that helps readers stay informed about current affairs and developments that matter to them. Her work highlights relevant stories, emerging trends, and key issues, presenting them in a balanced, accessible, and reader-friendly way.
More Stories
What Is a Blue Moon and When Can You See It in the UK?
LHC Achieves Key Milestone in 2026 Physics Programme
Why Rare Earth Metals for Electric Cars Are Crucial for Modern Mobility